Showing 2 posts of 2 posts found.
The FDA has approved its first treatment for peanut allergy in patients between ages four and 17. The drug is …
US biopharmaceutical firm Aimmune has revealed that its peanut allergy candidate AR101 hit its primary endpoint in the largest trial …
Tezspire improves symptoms and tissue inflammation in phase 3 EoE trial
Highlighting the value of lab research for healthcare innovation
Capital Dynamics invests €14m in Italian community healthcare platform CareHub
Medtronic secures CE Mark for new cardiac pacing portfolio
Dermatology leader Doncker is new Onicor CEO